E-mail this story
Botox gets FDA nod for chronic migraine
The makers of the miracle toxin that erases frown lines by paralyzing facial muscles won the Food and Drug Administration's blessing on Friday to market Botox for the prevention of chronic migraine headaches. The FDA's decision expands the potential market for Botox, which burst upon the American cosmetic scene in the late 1980s, to 12% of the U.S. population -- the proportion of Americans thought to suffer from the throbbing, pulsating pain of migraine headaches.
October 15, 2010